| Brian Gage |
Media Assistance:
 Diane Duke Williams Media Coordinator williamsdia@wustl.edu (314) 286-0111 |
|
|
| News Stories & Tip Sheets: |
|
Showing 1 Stories. |
|
| Consequences of warfarin Common blood thinner increases risk of bone fracture (http://mednews.wustl.edu/news/page/normal/6422.html) Jan. 23, 2006 -- Elderly patients taking the commonly prescribed blood thinner warfarin experience an increased risk for osteoporosis-linked bone fractures, according to a study at the School of Medicine. The results suggest physicians should carefully monitor the bone health of patients placed on the medication and that their patients should take steps to decrease the risk of osteoporosis. |
|
Showing 1 Stories. |
|
| Clips: |
|
Showing Clips 1 through 3 of 4. - Show More |
 Show More Clips |
|
| Which Genetic Tests are Really Worth Getting?
The Wall Street Journal May 1, 2008 -- With Congress poised to eliminate a big barrier to genetic testing for risk of certain diseases, consumers still face challenges in figuring out which ones offer useful information. Despite heavy marketing by some genetic-test makers, the wide use of genetic tests has been held back by a variety of factors, including questions about the tests' usefulness and concerns that results could be used by employers and insurers to discriminate against people. Critics argue that many tests can't accurately identify which people are at risk for various illnesses. WUSTL medical researcher Brian Gage comments. Includes Web links to learn more about genetic testing. |
| FDA notes role genetic testing can play in safer use of blood thinner
Associated Press and 65 others Aug. 17, 2007 -- Federal health officials are stopping short of recommending genetic tests for patients on the blood-thinner warfarin, even though they have said such screenings could prevent thousands of complications each year. Warfarin became the first widely used drug to include genetic testing information on its label. The information can help doctors determine how best to prescribe the drug. The FDA said this means personalized medicine is no longer an abstract concept but has moved into the mainstream. "What we need to do is find out whether genetic testing improves outcomes," said WUSTL medical researcher Brian Gage. |
| In milestone, FDA pushes genetic tests tied to drug
The Wall Street Journal Aug. 16, 2007 -- A case featuring a St. Louis woman and the powerful blood thinner called warfarin shows the advances in personalized medicine, where treatment is tailored to an individual's genetic makeup. But, in a possible harbinger of battles to come, the warfarin tests have also led to a clash between the FDA and some doctors. WUSTL medical researcher Brian Gage comments. |
|
Related Information Related Groups:
|